Previous 10 | Next 10 |
LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, Nuance Pharma, has dosed the...
2023-04-04 17:08:18 ET Gainers: Roivant Sciences ( ROIV ) +5% . Leonardo DRS ( DRS ) +4% . Kura Sushi USA ( KRUS ) +4% . SomaLogic ( SLGC ) +4% . Accolade ( ACCD ) +4% . Losers: Verona Pharma ( VRNA ) -4...
2023-03-28 12:18:44 ET Summary Lead drug candidate had positive results in 2 Phase 3 trials. If its marketing application is submitted in a timely fashion, it should get reviewed and approved next year. Sales are likely to surpass that of recently approved nebulizer solutions....
2023-03-27 02:31:17 ET Summary Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4, targeting both bronchodilation and inflammation. Positive Phase 3 results from the ENHANCE trials show significant improvements in lung function, ...
2023-03-15 11:44:07 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stoc...
2023-03-12 04:00:11 ET Summary Verona Pharma's ensifentrine achieved positive results in a Phase 3 study with an indication for COPD. Ensifentrine is also in Phase 2 studies to address asthma and cystic fibrosis. Long-term estimates have ensifentrine as a potential blockbuster...
2023-03-07 12:03:10 ET Verona Pharma plc (VRNA) Q4 2022 Earnings Conference Call March 07, 2023, 09:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Kathleen Rickard - Chief Medical Office...
2023-03-07 09:53:47 ET The following slide deck was published by Verona Pharma plc in conjunction with their 2022 Q4 earnings call. For further details see: Verona Pharma plc 2022 Q4 - Results - Earnings Call Presentation
2023-03-07 06:14:49 ET Verona Pharma press release ( NASDAQ: VRNA ): Q4 GAAP EPS of -$0.02 beats by $0.03 . Cash and cash equivalents at December 31, 2022, were $227.8 million (December 31, 2021: $148.4 million). The Company believes cash and cash equivalents at De...
Transformational results in Phase 3 ENHANCE program for COPD NDA submission expected Q2 2023 Strong balance sheet to support planned US commercial launch Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., March 07, 2023 (GLOBE NEWSWIRE...
News, Short Squeeze, Breakout and More Instantly...
2024-07-05 11:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 07:00:04 ET Raghuram Selvaraju from H.C. Wainwright issued a price target of $36.00 for VRNA on 2024-06-27 06:09:00. The adjusted price target was set to $36.00. At the time of the announcement, VRNA was trading at $14.69. The overall price target consensus is...
Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIG...